“Femarelle®… hemmer overgangssymptomer uten risiko for blodpropp…”

The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women

RESULTS:
Pretreatment study of all seven women with shortened closure times confirmed
abnormalities associated with thrombophilia: four women were heterozygous for the factor
V Leiden gene mutation, one was heterozygous for the prothrombin gene mutation, one was
found to have protein S deficiency, and one had increased anticardiolipin antibodies. All
participants reported improved symptoms during the treatment period. No significant
change in closure times was found in the normally clotting participants after 3 or 8 weeks
of Femarelle therapy (P > 0.26). No significant change in closure time was seen in the seven
thrombophilic women after 3 or 8 weeks or 1 year of Femarelle treatment (P > 0.26). The
regression curve for measures over time was not significant (P = 0.26).

Les mer>>>

 

Leave a Reply